GLAXOSMITHKLINE AND ADOLOR ANNOUNCE THE COMPLETION OF ENROLLMENT OF PIVOTAL CLINICAL STUDIES OF ENTEREG

GlaxoSmithKline and Adolor Corporation announced today that GSK has completed enrollment of the Phase 3 clinical program to evaluate the efficacy and safety of the oral investigational drug Entereg (alvimopan) for the treatment of gastrointestinal adverse events caused by opioids used for persistent non-cancer pain.
Genetic Engineering News